Why molecular modeling runs into manual brute-force
The classic search cycle starts with a compound library — hundreds of thousands of structures. They are run through docking, ranked by calculated binding energy, and the top of the list is handed to chemists.
Then manual work begins: an expert reviews the molecules by eye, crosses out similar and suspicious ones, and keeps the criteria in their head.
This is where molecular modeling hits a bottleneck. Docking answers one question — how tightly a molecule fits into a protein pocket. It says nothing about solubility, metabolic stability, and toxicity, yet this set determines a candidate's fate.
Synthesis therefore starts late, and chemists receive compounds that are certain not to make it to the clinic.
The cost of delay is measurable. Synthesis and initial testing of a series take weeks of lab work, and if failure comes at a late stage, the entire branch closes at once.
Drug candidate selection turns into a lottery where the result depends on a particular person's intuition rather than a reproducible criterion.
Computational chemistry removes this limitation: early compound filtering is built as a cascade of filters, where virtual screening scores tens of thousands of molecules before the first flask appears.
Calculations run on AutoDock Vina and open cheminformatics libraries, and predefined thresholds make the decision, not the expert's eye. We explain how this is addressed in practice.
What changes: candidate selection speed and hypothesis quality
The first measurable shift is in hypothesis search speed.
A compound activity prediction model scores a library of hundreds of thousands of molecules overnight and gives chemists a ranked list, whereas manual selection with sequential synthesis yields a few validated compounds per week.
The gap in practice is an order of magnitude: what used to stretch over a quarter now fits into two to three weeks.
The second effect is toxicity assessment before synthesis. Separate models calculate the probability of cardio-, hepato-, and mutagenicity, and a compound with a poor profile drops out at the calculation stage, before reaching the flask.
Before synthesis, 90–95% of unpromising candidates are filtered out — instead of spending weeks on producing substance, the team spends them on the small fraction that has a chance to reach preclinical trials.
Hence the main consequence: an entire class of failures disappears — those that surfaced late, when a compound had already been synthesized, tested in several series, and deemed unsuitable.
False candidates are filtered out not by a single metric but by the consensus decision of several models, so the filtering does not cut promising molecules.
Hypothesis quality increases because every assessment comes with an applicability domain and an uncertainty measure. The chemist sees not a bare score but compounds where the model is confident and those where the prediction is shaky and needs validation.
This is what makes ranking suitable for decisions rather than decorative: priority goes to molecules with a real structure-activity relationship, not random hits from the training set.
Operating modes: screening, generative design, simulation
The modes differ not in "power" but in what question they address and what cost of error they carry. Screening answers "what looks like active"; generative design — "what is not yet in libraries"; dynamics — "does the bond hold over time".
Mixing them into one protocol without distinguishing selection criteria is a typical source of false hits that are then expensive to verify by synthesis.
| Mode | When suitable | Limitations |
|---|---|---|
| Virtual screening | Target is known, compound library is available, a ranked list of hits is needed | Accuracy of scoring functions depends on target class; some hits will be false |
| Generative molecular design | Binding site structure is known, new scaffolds are needed rather than enumeration of existing ones | Synthesizability, toxicity, and stability lie outside the model — external filters are needed |
| Molecular dynamics | We confirm complex stability and bond behavior in an aqueous environment | Long computation for a short trajectory fragment; result is sensitive to force field choice |
| Hybrid protocol: screening → dynamics | Need to cut the false hit rate before ordering synthesis | Requires unified selection criteria and protocol alignment between stages |
Practical rule: broad screening first, then dynamics on a short list, and generative design is connected when enumeration is exhausted.
We fix selection criteria and reproducibility metrics before calculation starts, so the result of the next stage verifiably continues the previous one rather than rewriting it.
Implementation stages: from problem statement to validation
Molecular modeling delivers a practical result only if the computational pipeline is assembled for a specific task rather than taken ready-made.
Therefore we start with the problem statement: which compound class is of interest, what experimental data has already been accumulated, and what accuracy is considered sufficient for the decision.
Then the work proceeds in stages, and each ends with an artifact that can be checked before moving to the next.
- Problem and data review: which properties we calculate, how long one pass may take, and what has already been confirmed by experiment.
- Dataset preparation: a unified structure format, removal of duplicates and broken records, labeling of known activities. We assemble the holdout set without intersections with the training set — otherwise validation will show inflated numbers.
- Calculation scheme: a chain from structure preparation to ranking, with explicit indication of where full recalculation is needed and where a fast estimate is enough.
- Implementation of the computational pipeline: a job queue and intermediate saves so a long calculation continues from a checkpoint rather than starting over.
- Model validation: confirmed compounds must land in the upper part of the list; we separately look at classes absent from training.
- Calculation protocol: versions of data and parameters plus a run log — the result is reproducible even a month later.
- Handover to the client's team: training, launch documentation, and review of typical failures.
We support the first independent calculations: discrepancies usually arise not in the model but in input data preparation — we resolve them on the spot.
What we hand over: datasets, models, protocols
The training pipeline is an asset that outlives the project. Therefore, along with the results, we hand over everything for independent work: from prepared datasets to the rules by which your specialists run calculations without our involvement.
- Model training dataset — cleaned and labeled sets with a description of sources, filtering rules, and splitting into training, validation, and test parts.
- Trained models and their cards — weights, training parameters, applicability domain, and known limitations; the model can be fine-tuned on new data.
- Calculation schemes — step-by-step scenarios for typical tasks: library screening, property assessment, candidate selection, with parameters for each step.
- Calculation reproducibility — versions of data and models, run logs, checksums of inputs and outputs: a repeated run gives the same result.
- Data access rules — roles, permission matrix, procedure for granting and revoking access, separation of public and confidential sets.
- Integration layer — scripts and call points for running calculations in your infrastructure, including a closed environment without external services.
- Model documentation — how to read metrics, where the applicability boundaries are, and which checks signal degradation under data drift.
Acceptance follows a checklist: for each item, your side independently runs the calculation and compares it with the reference. Handover is complete when the full cycle runs without our support.
Case study: molecular modeling for a series of inhibitors
The client was looking for inhibitors against a specific target and encountered a standard problem: many candidates, expensive validation. The input library was several hundred compounds, and each went through one route: synthesis, then enzyme assay.
An iteration took six to eight weeks, and the share of compounds with confirmed activity stayed around four percent.
We built a target model on published structures from Protein Data Bank, refined the binding site, and checked its stability across different protein conformations.
Then ligand binding prediction was run across the entire library: compounds were ranked by calculated energy and the geometry of contacts with key residues.
Only the top of the list was synthesized — 24 compounds instead of 400. Activity was confirmed for nine: about forty percent versus the previous four.
The number of syntheses per finding dropped by roughly fifteen times, and the inhibitor search cycle shrank to two to three weeks — the lab became the bottleneck, not selection.
Test results were returned to the model: confirmed and refuted bindings became a training set for the scoring function, so ranking in the next round was refined.
We separately calculated the share of active compounds in the first percentages of the list and compared it with random selection — this checked that the calculation does not produce false positives.
Calculation does not replace experiment and does not guarantee activity for every compound. It changes the order of work: expensive validation goes through a short list instead of the entire library.
How does AI modeling differ from classical docking?
Classical docking is physically grounded enumeration: the ligand is placed in the binding site in different positions and conformations, and contact strength is calculated by a scoring function — the sum of van der Waals, electrostatic, and hydrogen contributions.
The strength of the approach is transparency: you can see which contacts produced the score. The weakness is the approximation of the function itself and the fact that protein mobility is almost not accounted for in the calculation.
Machine learning in drug development comes in where this approximation starts to cost more than calculation time.
The model is trained on "structure — measured activity" series, and it predicts binding energy from the statistics of real measurements rather than simplified physics.
The gain appears in two cases: when a very large compound library needs to be ranked quickly and when the physics is poorly described — allosteric sites, water-mediated contacts, noticeable conformational mobility.
When docking does not work, it is visible by discrepancy, not intuition.
The signs are: the predicted position of the molecule in the site does not explain differences in activity within a series; different scoring functions give scatter greater than the observed effect; activity is determined by kinetics or metabolism rather than binding geometry.
Here adding a machine model to docking is pointless — a different data source is needed, usually experiment.
The difference between computational approaches lies in the very question they answer. Docking says how a molecule fits into the pocket; a machine model says how likely it is to be active at all.
Binding prediction accuracy is higher for models on series similar to the training set but drops noticeably outside it, whereas physical calculation is more robust to unfamiliar compound classes.
Therefore, in a project the methods do not compete: the model filters the library down to hundreds of candidates, docking refines geometry and contacts, and a few of the best go to synthesis and measurement.
We start with what exactly limits the project — enumeration volume, ranking accuracy, or the absence of reliable measurements — and assemble a combination of methods for that constraint.
If there is enough data to train a model, it takes over primary selection; if not, we honestly stay with physical calculation and hypothesis validation by experiment.
Frequent technical doubts before starting a project
Doubts at the start are usually not about the idea itself but about whether the model will withstand laboratory validation and whether compound structures will leak. Below are the four most frequently asked questions, with engineering answers.
How reliable is the model's prediction?
The model does not replace experiment; it ranks candidates so the lab spends time on the top lines of the list. We calibrate it on a holdout set, calculate prediction error and, separately, accuracy at the top of the rank, and add an uncertainty estimate to each prediction.
Chemical classes where the model extrapolates poorly are put in a separate list: they need experimental validation, and the client sees this before synthesis, not after.
We have little proprietary experimental data
We start with open datasets and transfer structural representations to them, then fine-tune on your measurements.
We fill the gap with molecular dynamics calculations, and select the next batch of compounds by the maximum uncertainty principle — each new lab data point most strongly refines the model exactly where it was wrong.
How does this integrate with the lab?
First we agree on the exchange format: structures, compound identifiers, measurement conditions. Then we deploy a wrapper that pulls results from your lab system and returns a candidate queue back.
If there is no unified log, at the start we work through agreed files and synchronization, and add a direct connection when the process stabilizes.
What about the confidentiality of structures?
We deploy the calculation in your environment or in a dedicated closed environment — compounds do not go to external services. Access is role-based, and each export is logged.
If data cannot be transferred at all, training runs on your site, and we receive only anonymized model quality metrics.
Let's discuss the task: what is needed from your side to start
To calculate rather than guess, a project start requires a minimum of input data: without a target structure and known chemistry, a trial calculation degenerates into enumeration. Below is what we request from the client.
Some items are covered in one conversation; the rest usually already lies in your reports and internal databases.
- Goal and success criterion — which target class, what we optimize: affinity, selectivity, solubility, or metabolic stability.
- Target structure — coordinates from open banks or a predicted model, binding site, cofactors, protonation state.
- Chemistry — a compound library in standard structure transfer formats, known active series with measured values.
- Data from past campaigns, including negative results: we use them to calibrate the scoring function and check that the model does not reproduce screening artifacts.
- Computational environment — where we run calculations, what access and data isolation rules apply on your side.
- Project constraints — deadlines, regulatory requirements, who on your side makes candidate selection decisions.
- Result format — a table of compounds with scores for synthesis, a report, or integration with your internal system.
This is enough to run a trial calculation on a small subset and align expectations before full launch. Describe the task — we will return with a timeline estimate and a plan where the first step takes days, not months.
